#Ireland #Dublin #Alkermes plc #Avadel Pharmaceuticals #Irish Takeover

Alkermes plc Provides Latest Opening Position Disclosure

On November 5, 2025, Alkermes plc (Nasdaq: ALKS) issued an important statement regarding its position in the ongoing takeover bid for Avadel Pharmaceuticals plc. This disclosure is made under Rule 8.1(a) and (b) of the Irish Takeover Panel Act, 1997.

Key Information About the Disclosure

The disclosure includes crucial details about the bidder and the target. Alkermes identifies itself as the offeror, indicating its role in the takeover process. The disclosure states that the latest position was held on November 3, 2025. Notably, this disclosure is a requirement for transparency, aiding potential investors and stakeholders in evaluating the implications of the takeover bid.

Details of Positions Held

Interestingly, the disclosure confirmed that there were no interests or short positions in the relevant securities of Avadel Pharmaceuticals or in other relevant companies at the time of the disclosure. In this context, it also notes that no financial engagements or stock positions were recorded, highlighting that the disclosure remains purely focused on the legal aspects of the offer.

Participation of Financial Advisors

The announcement also mentions J.P. Morgan, which is assisting Alkermes as its financial advisor. However, it is important to clarify that the shares held by J.P. Morgan are not owned on behalf of Alkermes. This point emphasizes the independence of advisory roles in the context of the takeover, a significant notion in merger and acquisition dynamics.

Summary of Interests

When detailing the interests of persons acting in concert with Alkermes, the disclosure lists minimal holdings. For instance, 55I, LLC holds 53 ordinary shares, a mere 0.0001% of the total capital, while JPMorgan Chase Bank holds 13,500 shares, representing 0.0139% of the total. This emphasizes the limited stake that external advisors and affiliated parties have in the transaction, preserving the integrity of the bid by minimizing perceived conflicts of interest.

Legal Compliance and Communication

The disclosure is part of compliance with the Irish Takeover Rules, a set of regulations designed to ensure that all stakeholders are adequately informed during takeover processes. By adhering to these guidelines, Alkermes aims to maintain a transparent bidding process while pursuing its strategic objectives.

Conclusion

In conclusion, the recent opening position disclosure by Alkermes plc signifies an important step in its ongoing takeover bid for Avadel Pharmaceuticals. With no significant positions or interests disclosed, the company ensures that it remains compliant with Irish takeover regulations while providing essential information to stakeholders. This move reflects Alkermes' commitment to transparency and integrity as it navigates the competitive landscape of pharmaceutical mergers and acquisitions. As the takeover progresses, market observers will be keenly watching how this situation develops and what further updates may emerge from Alkermes in the coming weeks.

For further information, interested parties may contact Sandy Coombs at Alkermes via phone at +1 781 609 6377.